- Commercial stage specialty pharmaceutical company Fennec Pharmaceuticals (NASDAQ:FENC) (TSX:FRX:CA) said that Adrian Haigh has departed from his position as Fennec’s COO as of June 30, 2024.
- After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as COO.
- “The company is actively searching for a U.S.-based leader,” said Rosty Raykov, CEO.
2024-07-01